Michael J. Grant MDClinical Fellow, Hematology and Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut
Dr. Michael Grant is a fellow at Yale Cancer Center associated with the Yale University School of Medicine. He is passionate about caring for patients with diverse hematologic and oncologic problems and has a clinical focus in thoracic and head and neck malignancies. Dr. Grant’s research focuses on optimizing targeted therapy in oncogene-driven lung cancer, immunotherapy approaches for the treatment of non-small cell lung cancer, and novel non-invasive approaches to early detection of lung cancer. This research involves a mix of clinical and translational projects as well as clinical trials. He has received a 2021 ASCO Conquer Cancer Young Investigator Award for his work investigating sensitivity and resistance mechanisms to tyrosine kinase inhibitors for patients with non-small cell lung cancer harboring uncommon EGFR exon 19 deletions.
Dr. Grant obtained his undergraduate degree with a dual major in Mathematics and Biology from Dickinson College in Carlisle, Pennsylvania where he also played collegiate basketball. He then graduated from the Albert Einstein School of Medicine in the Bronx, New York where he obtained his MD. His residency in Internal Medicine was completed at Duke University Hospital, Duke University School of Medicine. He is board certified in internal medicine. He is currently in his final year of hematology and medical oncology fellowship training at the Yale University School of Medicine where he is also enrolled in the Yale Cancer Center T32 Advance Training Program for Physician-Scientists.
Recent Contributions to PracticeUpdate:
- Navigating the New Neoadjuvant Paradigm in Resectable NSCLC
- EGFR Exon 20 Insertions: Welcoming the New Treatment Paradigm
- Resectable Lung Adenocarcinoma — Yes to Immunotherapy, but When?
- Acquired Resistance to Osimertinib in EGFR Mutant NSCLC
- Isolated CNS Recurrence After Definitive Therapy for Stage III NSCLC
- First-Line Therapy for Metastatic Squamous Lung Cancer With PD-L1 0%
- ALK-Rearranged Oligometastatic NSCLC
- A 76-Year-Old Man With COPD and Metastatic Lung Adenocarcinoma
- Advanced NSCLC: Anti-PD-1 Rechallenge After Immune-Related Toxicity
- Stage IIIB Lung Adenocarcinoma With EGFR L858R Mutation